tradingkey.logo
tradingkey.logo
Search

NextCure Inc

NXTC
Add to Watchlist
4.145USD
-0.885-17.59%
Close 07-31 16:00ETQuotes delayed by 15 min
14.95MMarket Cap
LossP/E TTM

Earnings Forecast

Currency: USD Updated: 2026-07-31
Previous score
8.00
Change
0.67
The current earnings forecast score of NextCure Inc is 8.67, ranking 74 out of 385 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 20.00 and a low of 15.00.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
17.500
Target Price
+248.61%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
NextCure Inc
NXTC
2
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

FAQs

What is NextCure Inc's price target?

Analysts forecast that NextCure Inc's price target is USD 18.00, with the highest forecast at USD 20.00 and the lowest forecast at USD 15.00.

How have NextCure IncNXTC's recent earnings per share performed?

The market expectation was USD -1.87, while NextCure IncNXTC's earnings per share (EPS) for the previous quarter was USD -2.37. EPS for the next quarter is expected at USD -1.93.

What is the analyst rating for NextCure Inc?

Based on the ratings of NextCure Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.